The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumors
Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides an overview of the Phase II TROPION-PanTumor03 trial (NCT05489211) of datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate (ADC) in patients with solid tumors. Cohorts include patients with gastric and colorectal cancer, where a number of patients have TROP2-positive tumors. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
